Advaxis Inc (ADXS) 14.44 $ADXS
Nasdaq stocks posting largest percentage increases
AP - 37 mins ago
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
ADXS: 14.44 (+1.00), CTRX: 59.54 (-0.29), PACB: 5.84 (-0.36), ICEL: 16.43 (+0.01), ALIM: 5.01 (+0.41), MARPS: 12.75 (+0.93), ATRA: 41.57 (-1.33), ASPX: 100.27 (-0.09), CCT.TO: 75.40 (-0.48), JAXB: 11.00 (+0.12), OFIX: 35.89 (+4.58), CNCE: 15.14 (-0.21)
Big Pharma Merger Monday Deals Disregard Biotech Bubble Talks
at The Street - Tue Mar 31, 8:39AM CDT
Large pharmas continued the shopping spree, paying no attention to whispers of a biotech bubble.
CTRX: 59.54 (-0.29), ADXS: 14.44 (+1.00), UNH: 118.29 (-2.71), HZNP: 25.97 (+0.19), IBB: 343.43 (-7.89), TEVA: 62.30 (-0.22), ASPX: 100.27 (-0.09), NVS: 98.61 (-2.70), HPTX: 45.90 (-0.08)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 8:11AM CDT
BDSI: 10.50 (-0.01), CRMD: 9.84 (+1.14), NCFT: 25.57 (-0.10), LEJU: 7.96 (-0.51), CTRX: 59.54 (-0.29), ZIOP: 10.77 (-0.84), ADXS: 14.44 (+1.00), CNAT: 7.12 (-0.41), XON: 45.37 (-0.93), BBEP: 5.48 (-0.07), ADMP: 3.94 (+0.11), CLDN: 18.94 (-2.73), ASPX: 100.27 (-0.09), HPTX: 45.90 (-0.08), GENE: 5.27 (+0.33), SYN: 2.19 (-0.10), ICEL: 16.43 (+0.01), HZNP: 25.97 (+0.19), OHRP: 2.54 (-0.27), SFUN: 6.00 (-0.35), CNET: 1.61 (-0.05)
Advaxis to Present at the Jefferies Immuno-Oncology Summit
GlobeNewswire - Thu Mar 26, 6:30AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that it will present at the 2015 Jefferies Immuno-Oncology Summit being held April 15, 2015 at the Boston Harbor Hotel in Boston, Massachusetts.
ADXS: 14.44 (+1.00)
Biotech Equities Technical Coverage - ZIOPHARM Oncology, Arrowhead Research, Merrimack Pharma, Vertex Pharma, and Advaxis
PR Newswire - Wed Mar 25, 8:41AM CDT
Editor Note: For more information about this release, please scroll to bottom.
MACK: 11.88 (+0.01), ADXS: 14.44 (+1.00), VRTX: 117.97 (-3.28), ZIOP: 10.77 (-0.84), ARWR: 6.76 (-0.24)
Cancer Therapy Stock Advaxis Will Benefit From IPO From Rival Aduro
at The Street - Mon Mar 23, 11:08AM CDT
Aduro is expected to IPO in early April. Advaxis, the other Listeria-based immunotherapy, will be a direct beneficiary as a result of the exposure from Aduro's IPO.
ADXS: 14.44 (+1.00), JUNO: 60.66 (-0.09)
Advaxis Announces First Patient Treated in Phase 1/2 Dose-Escalation Study of ADXS-HPV for Recurrent Cervical Cancer
GlobeNewswire - Thu Mar 19, 6:30AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced that the first patient was dosed in a Phase 1/2 clinical trial evaluating higher doses and repeat cycles of ADXS-HPV (ADXS11-001), an investigational Lm-LLO immunotherapy, for the treatment of patients with recurrent cervical cancer.
ADXS: 14.44 (+1.00)
Advaxis's Lm-LLO Immunotherapy Platform to be Featured in Three Poster Presentations at the 2015 American Association for Cancer Research Annual Meeting
GlobeNewswire - Wed Mar 18, 12:12PM CDT
Late Breaking Abstract to Highlight Enhanced Anti-Tumor Efficacy of ADXS-HPV (ADXS11-001) in Combination with OX40 and GITR Co-Stimulatory Molecule Monoclonal Antibodies
ADXS: 14.44 (+1.00)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 11:45AM CDT
SCON: 1.41 (-0.01), NES: 3.56 (+0.15), ADXS: 14.44 (+1.00), PRTS: 2.17 (-0.08), PFIE: 1.35 (-0.03), MVIS: 3.43 (-0.09), NSLP: 4.90 (-0.13), TRIL: 20.23 (+0.52), VRML: 1.77 (-0.07), DSKY: 7.09 (+0.15), STRL: 4.52 (-0.15), INO: 8.16 (-0.17), ENZ: 2.95 (-0.08), ICEL: 16.43 (+0.01), MTL: 1.24 (-0.11), MSO: 6.50 (+0.12), HELI: 1.33 (+0.08), PKOH: 52.67 (+0.69), OGEN: 1.02 (-0.03), BLPH: 9.18 (-0.17)
Why Advaxis, Inc. Stock Ripped Higher Today
George Budwell, The Motley Fool - Motley Fool - Mon Mar 16, 10:37AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of the clinical-stage biotech Advaxis ...
ADXS: 14.44 (+1.00), MRK: 57.48 (-0.86), AZN: 68.43 (-1.51)
Advaxis Presents Preliminary Data From a Phase 1/2 Trial of ADXS-HPV in HPV-Associated Anal Cancer in Combination With Chemoradiation Showing Complete Response and No Recurrences to Date in All Treated Patients
GlobeNewswire - Mon Mar 16, 6:30AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage cancer immunotherapy company, presented preliminary data from the Phase 1/2 clinical study of its lead immunotherapy product candidate, ADXS-HPV (ADXS11-001), in 10 patients with HPV-associated locally advanced anal cancer indicating that all patients who have completed treatment in the study have had a complete response with no evidence of recurrence to date (follow-up ranging from 0.5 - 24 months). The preliminary data also show that the investigational immunotherapy was well tolerated by the treated patients, and all treatment-related toxicities were within 24 hours of dosing, the most frequent of which include chills/rigors, fever and nausea.
ADXS: 14.44 (+1.00)
Esophageal Cancer Therapeutics Pipeline Review 2015 - 40 Companies & 57 Drug Profiles
M2 - Wed Mar 11, 7:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2mqnm8/esophageal_cancer) has announced the addition of the "Esophageal Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advantagene, Inc. - Advaxis, Inc. - Amgen Inc. - ArQule, Inc. - Aslan Pharmaceuticals Pte. Ltd. - AstraZeneca PLC - AVEO Pharmaceuticals, Inc. - Bellicum Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cellectar Biosciences, Inc. - Cerulean Pharma, Inc. - Daiichi Sankyo Company, Limited - Genmab A/S - GlaxoSmithKline plc - Glycotope GmbH - Hutchison MediPharma Limited - ImmunoFrontier, Inc. - ImmunoGen, Inc. - Immunomedics, Inc. - Karyopharm Therapeutics, Inc. - Mebiopharm Co., Ltd. - Meiji Seika Pharma Co., Ltd. - Merrimack Pharmaceuticals, Inc. - Novartis AG - Omeros Corporation - Omnitura Therapeutics Inc. - Oncolys BioPharma Inc. - Ono Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/2m...eal_cancer
CLRB: 3.11 (+0.06), IMMU: 3.83 (-0.06), ADXS: 14.44 (+1.00), CERU: 9.01 (-0.49), IMGN: 8.95 (+0.43), ARQL: 2.24 (unch), AMGN: 159.85 (-4.45), GSK: 46.15 (-1.05), BMY: 64.50 (-1.26), OMER: 22.03 (-0.36), MACK: 11.88 (+0.01), BLCM: 23.17 (+0.52), AZN: 68.43 (-1.51), AVEO: 1.45 (+0.01), NVS: 98.61 (-2.70), KPTI: 30.61 (-0.30), CELGZ: 2.97 (+0.16)
Gynecologic Oncology Group (GOG) Commences Enrollment in Stage 2 of GOG-0265 Clinical Trial
GlobeNewswire - Wed Mar 11, 6:30AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that the Gynecologic Oncology Group (GOG), now part of NRG Oncology, has enrolled the first patient in Stage 2 of its ongoing Phase 2 open-label clinical study of ADXS-HPV in patients with persistent or recurrent cervical cancer with documented disease progression. GOG-0265 has been amended to allow patients in Stage 2 to continue to receive repeat cycles of therapy until progression.
ADXS: 14.44 (+1.00)
Advaxis to Present at the Cowen and Company 35th Annual Health Care Conference
GlobeNewswire - Mon Mar 02, 6:30AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that Daniel J. O'Connor, President and Chief Executive Officer of Advaxis, will present at the Cowen and Company 35th Annual Health Care Conference being held March 2-4, 2015, at the Boston Marriott Copley Place in Boston, MA.
ADXS: 14.44 (+1.00)
First Week of ADXS October 16th Options Trading
StockOptionsChannel.com - Fri Feb 27, 9:44AM CST
Investors in Advaxis, Inc. saw new options become available this week, for the October 16th expiration.
ADXS: 14.44 (+1.00)
5 Stocks Insiders Love Right Now: GE, Mondelez and More
at The Street - Wed Feb 25, 6:00AM CST
Insiders at these companies have been scooping up shares of their own stock lately.
GE: 24.81 (-0.31), ADXS: 14.44 (+1.00), MDLZ: 36.09 (-0.41), MDGN: 8.06 (-0.16), MDAS: 18.82 (-0.03)
Nasdaq stocks posting largest percentage increases
AP - 37 mins ago
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
ADXS: 14.44 (+1.00), CTRX: 59.54 (-0.29), PACB: 5.84 (-0.36), ICEL: 16.43 (+0.01), ALIM: 5.01 (+0.41), MARPS: 12.75 (+0.93), ATRA: 41.57 (-1.33), ASPX: 100.27 (-0.09), CCT.TO: 75.40 (-0.48), JAXB: 11.00 (+0.12), OFIX: 35.89 (+4.58), CNCE: 15.14 (-0.21)
Big Pharma Merger Monday Deals Disregard Biotech Bubble Talks
at The Street - Tue Mar 31, 8:39AM CDT
Large pharmas continued the shopping spree, paying no attention to whispers of a biotech bubble.
CTRX: 59.54 (-0.29), ADXS: 14.44 (+1.00), UNH: 118.29 (-2.71), HZNP: 25.97 (+0.19), IBB: 343.43 (-7.89), TEVA: 62.30 (-0.22), ASPX: 100.27 (-0.09), NVS: 98.61 (-2.70), HPTX: 45.90 (-0.08)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 8:11AM CDT
BDSI: 10.50 (-0.01), CRMD: 9.84 (+1.14), NCFT: 25.57 (-0.10), LEJU: 7.96 (-0.51), CTRX: 59.54 (-0.29), ZIOP: 10.77 (-0.84), ADXS: 14.44 (+1.00), CNAT: 7.12 (-0.41), XON: 45.37 (-0.93), BBEP: 5.48 (-0.07), ADMP: 3.94 (+0.11), CLDN: 18.94 (-2.73), ASPX: 100.27 (-0.09), HPTX: 45.90 (-0.08), GENE: 5.27 (+0.33), SYN: 2.19 (-0.10), ICEL: 16.43 (+0.01), HZNP: 25.97 (+0.19), OHRP: 2.54 (-0.27), SFUN: 6.00 (-0.35), CNET: 1.61 (-0.05)
Advaxis to Present at the Jefferies Immuno-Oncology Summit
GlobeNewswire - Thu Mar 26, 6:30AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that it will present at the 2015 Jefferies Immuno-Oncology Summit being held April 15, 2015 at the Boston Harbor Hotel in Boston, Massachusetts.
ADXS: 14.44 (+1.00)
Biotech Equities Technical Coverage - ZIOPHARM Oncology, Arrowhead Research, Merrimack Pharma, Vertex Pharma, and Advaxis
PR Newswire - Wed Mar 25, 8:41AM CDT
Editor Note: For more information about this release, please scroll to bottom.
MACK: 11.88 (+0.01), ADXS: 14.44 (+1.00), VRTX: 117.97 (-3.28), ZIOP: 10.77 (-0.84), ARWR: 6.76 (-0.24)
Cancer Therapy Stock Advaxis Will Benefit From IPO From Rival Aduro
at The Street - Mon Mar 23, 11:08AM CDT
Aduro is expected to IPO in early April. Advaxis, the other Listeria-based immunotherapy, will be a direct beneficiary as a result of the exposure from Aduro's IPO.
ADXS: 14.44 (+1.00), JUNO: 60.66 (-0.09)
Advaxis Announces First Patient Treated in Phase 1/2 Dose-Escalation Study of ADXS-HPV for Recurrent Cervical Cancer
GlobeNewswire - Thu Mar 19, 6:30AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced that the first patient was dosed in a Phase 1/2 clinical trial evaluating higher doses and repeat cycles of ADXS-HPV (ADXS11-001), an investigational Lm-LLO immunotherapy, for the treatment of patients with recurrent cervical cancer.
ADXS: 14.44 (+1.00)
Advaxis's Lm-LLO Immunotherapy Platform to be Featured in Three Poster Presentations at the 2015 American Association for Cancer Research Annual Meeting
GlobeNewswire - Wed Mar 18, 12:12PM CDT
Late Breaking Abstract to Highlight Enhanced Anti-Tumor Efficacy of ADXS-HPV (ADXS11-001) in Combination with OX40 and GITR Co-Stimulatory Molecule Monoclonal Antibodies
ADXS: 14.44 (+1.00)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 11:45AM CDT
SCON: 1.41 (-0.01), NES: 3.56 (+0.15), ADXS: 14.44 (+1.00), PRTS: 2.17 (-0.08), PFIE: 1.35 (-0.03), MVIS: 3.43 (-0.09), NSLP: 4.90 (-0.13), TRIL: 20.23 (+0.52), VRML: 1.77 (-0.07), DSKY: 7.09 (+0.15), STRL: 4.52 (-0.15), INO: 8.16 (-0.17), ENZ: 2.95 (-0.08), ICEL: 16.43 (+0.01), MTL: 1.24 (-0.11), MSO: 6.50 (+0.12), HELI: 1.33 (+0.08), PKOH: 52.67 (+0.69), OGEN: 1.02 (-0.03), BLPH: 9.18 (-0.17)
Why Advaxis, Inc. Stock Ripped Higher Today
George Budwell, The Motley Fool - Motley Fool - Mon Mar 16, 10:37AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of the clinical-stage biotech Advaxis ...
ADXS: 14.44 (+1.00), MRK: 57.48 (-0.86), AZN: 68.43 (-1.51)
Advaxis Presents Preliminary Data From a Phase 1/2 Trial of ADXS-HPV in HPV-Associated Anal Cancer in Combination With Chemoradiation Showing Complete Response and No Recurrences to Date in All Treated Patients
GlobeNewswire - Mon Mar 16, 6:30AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage cancer immunotherapy company, presented preliminary data from the Phase 1/2 clinical study of its lead immunotherapy product candidate, ADXS-HPV (ADXS11-001), in 10 patients with HPV-associated locally advanced anal cancer indicating that all patients who have completed treatment in the study have had a complete response with no evidence of recurrence to date (follow-up ranging from 0.5 - 24 months). The preliminary data also show that the investigational immunotherapy was well tolerated by the treated patients, and all treatment-related toxicities were within 24 hours of dosing, the most frequent of which include chills/rigors, fever and nausea.
ADXS: 14.44 (+1.00)
Esophageal Cancer Therapeutics Pipeline Review 2015 - 40 Companies & 57 Drug Profiles
M2 - Wed Mar 11, 7:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2mqnm8/esophageal_cancer) has announced the addition of the "Esophageal Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advantagene, Inc. - Advaxis, Inc. - Amgen Inc. - ArQule, Inc. - Aslan Pharmaceuticals Pte. Ltd. - AstraZeneca PLC - AVEO Pharmaceuticals, Inc. - Bellicum Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cellectar Biosciences, Inc. - Cerulean Pharma, Inc. - Daiichi Sankyo Company, Limited - Genmab A/S - GlaxoSmithKline plc - Glycotope GmbH - Hutchison MediPharma Limited - ImmunoFrontier, Inc. - ImmunoGen, Inc. - Immunomedics, Inc. - Karyopharm Therapeutics, Inc. - Mebiopharm Co., Ltd. - Meiji Seika Pharma Co., Ltd. - Merrimack Pharmaceuticals, Inc. - Novartis AG - Omeros Corporation - Omnitura Therapeutics Inc. - Oncolys BioPharma Inc. - Ono Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/2m...eal_cancer
CLRB: 3.11 (+0.06), IMMU: 3.83 (-0.06), ADXS: 14.44 (+1.00), CERU: 9.01 (-0.49), IMGN: 8.95 (+0.43), ARQL: 2.24 (unch), AMGN: 159.85 (-4.45), GSK: 46.15 (-1.05), BMY: 64.50 (-1.26), OMER: 22.03 (-0.36), MACK: 11.88 (+0.01), BLCM: 23.17 (+0.52), AZN: 68.43 (-1.51), AVEO: 1.45 (+0.01), NVS: 98.61 (-2.70), KPTI: 30.61 (-0.30), CELGZ: 2.97 (+0.16)
Gynecologic Oncology Group (GOG) Commences Enrollment in Stage 2 of GOG-0265 Clinical Trial
GlobeNewswire - Wed Mar 11, 6:30AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that the Gynecologic Oncology Group (GOG), now part of NRG Oncology, has enrolled the first patient in Stage 2 of its ongoing Phase 2 open-label clinical study of ADXS-HPV in patients with persistent or recurrent cervical cancer with documented disease progression. GOG-0265 has been amended to allow patients in Stage 2 to continue to receive repeat cycles of therapy until progression.
ADXS: 14.44 (+1.00)
Advaxis to Present at the Cowen and Company 35th Annual Health Care Conference
GlobeNewswire - Mon Mar 02, 6:30AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that Daniel J. O'Connor, President and Chief Executive Officer of Advaxis, will present at the Cowen and Company 35th Annual Health Care Conference being held March 2-4, 2015, at the Boston Marriott Copley Place in Boston, MA.
ADXS: 14.44 (+1.00)
First Week of ADXS October 16th Options Trading
StockOptionsChannel.com - Fri Feb 27, 9:44AM CST
Investors in Advaxis, Inc. saw new options become available this week, for the October 16th expiration.
ADXS: 14.44 (+1.00)
5 Stocks Insiders Love Right Now: GE, Mondelez and More
at The Street - Wed Feb 25, 6:00AM CST
Insiders at these companies have been scooping up shares of their own stock lately.
GE: 24.81 (-0.31), ADXS: 14.44 (+1.00), MDLZ: 36.09 (-0.41), MDGN: 8.06 (-0.16), MDAS: 18.82 (-0.03)
